SOURCE: digiMedical Solutions, Inc.

March 05, 2008 09:15 ET

Micros Report Initiates Research Coverage on digiMedical Solutions, Inc., With Fair Value Target Price of $0.30 or Potentially Higher vs. Recent Close of $0.09

COLLEYVILLE, TX--(Marketwire - March 5, 2008) - digiMedical Solutions, Inc. (PINKSHEETS: DGMS), a digital prescription software and pharmacy company, announced today that Micros Report has initiated research coverage of digiMedical Solutions and has issued a report reviewing the Company's historical operations and 2008 business plan. digiMedical went public through a reverse merger in 2006, and Micros Report is the first to provide research analysis on the company. The company has grown from a zero revenue start up in June of 2005 to a forecasted $10 million in sales in 2008. digiMedical Solutions, a Microsoft Partner, has created a new breed of pharmacy, integrating its own suite of proprietary software handling prescriptions digitally and securely from the physician's office into company owned "brick and mortar" pharmacies.

According to the report, prescription drug sales and utilization are growing rapidly and the market is expected to grow by 148% by 2016 to nearly $500 billion in sales.

Michael Willingham, Micros Report Director of Research, authored the report which includes a Fair Value Target price for DGMS of $0.30. This valuation is based on company characteristics that give it the potential to trade in a range as high as $0.89 vs. the recent close of $0.09.

Mr. Willingham and the report stated the following in determining this target:

--  "digiMedical's proprietary technology solution positions the company
    to profit from both the traditional existing pharmacy market space and the
    future of digital prescription fulfillment."
    
--  "DGMS has a proprietary software solution that drives drug
    prescriptions directly from physicians to the Company's own retail pharmacy
    stores, which is a great way to ensure a recurring sales flow."
    
--  "By differentiating its business model, the share price of DGMS common
    stock should enjoy a higher multiple than industry competitors."
    
--  "With pending legislation that may require the use of digital
    prescription technology, larger chain pharmacies may have interest in the
    digital prescription software solution alone."
    

The report will be available soon at http://www.digimedical.com/news/news.aspx under "Featured Presentation." Interested parties may also access the report by going to the www.MicrosReport.com homepage later today or by emailing ir@digimedical.com and requesting a copy.

Please see important disclosures at the end of the report.

To be added to digiMedical's corporate e-mail list for shareholders and interested investors, please send an e-mail to ir@digimedical.com.

About digiMedical Solutions, Inc.™ (www.digiMedical.com)

digiMedical Solutions, Inc.™ is a pharmacy and medical technology company focused on developing next generation, digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that closely align the doctor, pharmacist and patient. The company's continued growth will come from three channels: direct marketing of the company's wireless based d-prescription technology to physicians, acquisition of independent pharmacy chains and the sale of select territories to "market partners" licensed to exploit the digiMedical Solutions™ model. digiMedical Solutions™ currently owns and operates five pharmacies throughout Texas and Florida and is a Microsoft Independent Software Vendor (ISV). digiMedical Solutions™ unique business model connects physicians, patients and pharmacies with next generation medical technologies.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as "Forward-Looking Statements" for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including "anticipate," "await," "envision," "foresee," "aim at," "believe," "intends," "estimates" including without limitation, those relating to the company's future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company's business and results of operations.

Contact Information